This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Reposal
- DrugBank Accession Number
- DB13805
- Background
Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Reposal (DB13805)
- Weight
- Average: 262.309
Monoisotopic: 262.131742448 - Chemical Formula
- C14H18N2O3
- Synonyms
- Not Available
- External IDs
- WT-161
- WT161
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Reposal. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Reposal. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Reposal. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Reposal. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Reposal. Alimemazine The risk or severity of CNS depression can be increased when Alimemazine is combined with Reposal. Almotriptan The risk or severity of CNS depression can be increased when Almotriptan is combined with Reposal. Alosetron The risk or severity of CNS depression can be increased when Alosetron is combined with Reposal. Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Reposal. Alverine The risk or severity of CNS depression can be increased when Alverine is combined with Reposal. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- N05CA12 — Reposal
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Barbituric acid derivatives
- Alternative Parents
- N-acyl ureas / Diazinanes / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- 1,3-diazinane / Aliphatic heteropolycyclic compound / Azacycle / Barbiturate / Carbonic acid derivative / Carbonyl group / Carboxylic acid derivative / Dicarboximide / Hydrocarbon derivative / N-acyl urea
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3T5TIX1AYI
- CAS number
- 3625-25-0
- InChI Key
- MKELYWOVSPVORM-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H18N2O3/c1-2-14(11(17)15-13(19)16-12(14)18)10-6-8-3-4-9(5-8)7-10/h6,8-9H,2-5,7H2,1H3,(H2,15,16,17,18,19)
- IUPAC Name
- 5-{bicyclo[3.2.1]oct-2-en-3-yl}-5-ethyl-1,3-diazinane-2,4,6-trione
- SMILES
- CCC1(C(=O)NC(=O)NC1=O)C1=CC2CCC(C2)C1
References
- General References
- KESSING SV, TARDING F, THOMSEN AC: [REPOSAL, A NEW HYPNOTIC. I. PHARMACODYNAMIC ACTIVITY]. Ugeskr Laeger. 1963 Dec 6;125:1735-8. [Article]
- KESSING SV, TARDING F, THOMSEN AC: [REPOSAL, A NEW HYPNOTIC. II. CLINICAL EFFECTS]. Ugeskr Laeger. 1963 Dec 6;125:1739-41. [Article]
- Nielsen P, Tarding F: The metabolic fate of 5-(bicyclo-3,2,1,-oct-2-en-2-yl)-5-ethyl barbituric acid, (Reposal). Acta Pharmacol Toxicol (Copenh). 1968;26(6):521-30. [Article]
- External Links
- ChemSpider
- 18167
- ChEBI
- 135079
- ChEMBL
- CHEMBL505851
- Wikipedia
- Reposal
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.182 mg/mL ALOGPS logP 1.88 ALOGPS logP 1.58 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 7.14 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 75.27 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 68.95 m3·mol-1 Chemaxon Polarizability 26.76 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at June 23, 2017 20:49 / Updated at June 12, 2020 16:53